| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 04/20/2000 | CA2343356A1 Methods for the production of antibodies to specific regions of cyclosporine and cyclosporine metabolites |
| 04/20/2000 | CA2314004A1 Matrix-remodeling genes |
| 04/19/2000 | EP0994187A1 Renin-active substance comprising human prorerin and antibodies to the prorerin profragment |
| 04/19/2000 | EP0993616A1 Reagent for detecting and monitoring viral infections |
| 04/19/2000 | EP0993613A2 Method for recognizing and determining gnrh receptors and the use of gnrh agonists and gnrh antagonists and other gnrh receptor ligands for the treatment with gnrh receptors of tumours originating in the brain and/or nervous system and/or meninges and/or of kaposi sarcoma |
| 04/19/2000 | EP0993470A2 Antibodies and other binding molecules specific for hepatitis b viral antigens |
| 04/19/2000 | EP0550561B1 Purification of cytokeratin fragments |
| 04/19/2000 | CN1251134A Neurotrophic factor NNT-1 |
| 04/19/2000 | CN1251130A Isolated viable parasate intestinal cells |
| 04/19/2000 | CN1250782A Process for preparing antibody able to precisely recognize difference between cells |
| 04/18/2000 | US6051697 Chemokine expressed in eosinophils |
| 04/18/2000 | US6051693 Human monoclonal antibody which preferentially binds to neoplastic cell over a normal cell of same tissue type; for diagnosis, anticarcinogenic agents and antitumor agents |
| 04/18/2000 | US6051691 Amino acid sequence of protein; for screening bactericides and bacteristats especially targeted to streptococci |
| 04/18/2000 | US6051690 NSP molecules |
| 04/18/2000 | US6051688 Amino acid sequence for polypeptide of at least 6 contiguous amino acids; for diagnosis and treatment of nervous system disorders; anticonvulsants; antiischemic/antihypoxic agents; antiepileptic agents; alzheimer's/parkinson's diseases |
| 04/18/2000 | US6051427 Retroviral packaging plasmid including retroviral helper dna lacking native enhancer and/or promoter of the viral 5' long terminal repeat, the psi function sequence and the 3' long terminal repeat, but encodes foreign regulatory sequences |
| 04/18/2000 | US6051418 Hybrid proteins with modified activity |
| 04/18/2000 | US6051405 An expression vector containing a dna segment that directs the synthesis of a recombinant fusion protein which is a single chain fab variable region from a modified pseudomonas exotoxin gene; producing improved toxins |
| 04/18/2000 | US6051404 A nucleic acid encoding a protein; vaccines for poultry |
| 04/18/2000 | US6051403 A dna molecule encoding a polypeptide having homology to sh2 domains as determined by blast-2 sequence alignment computer program; modulating intracellular signaling pathways |
| 04/18/2000 | US6051396 Method for producing retinoblastoma gene protein products |
| 04/18/2000 | US6051387 Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies |
| 04/18/2000 | US6051384 Method of detecting p53-specific antibodies |
| 04/18/2000 | US6051375 Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses |
| 04/18/2000 | US6051374 Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use |
| 04/18/2000 | US6051230 For treatment and/or diagnosis (imaging) of vascularized solid tumors |
| 04/18/2000 | US6051229 Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions |
| 04/18/2000 | US6051228 Antibodies against human CD40 |
| 04/18/2000 | US6051227 Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| 04/18/2000 | US6051226 use of antibodies targeting the MN oncoprotein conjugated to an anticancer therapeutic agent such as drug or toxin for tissue targeted cancer therapy |
| 04/18/2000 | US6051225 Family of high affinity, modified antibodies for cancer treatment |
| 04/18/2000 | US6051224 Compositions and methods for targeting cells and modulating pulmonary surfactant secretion |
| 04/18/2000 | US6051222 Cancer diagnosis; genetic engineering |
| 04/16/2000 | CA2284857A1 G protein coupled receptor a4 |
| 04/13/2000 | WO2000020864A1 Immunotherapy of b cell involvement in progression of solid, nonlymphoid tumors |
| 04/13/2000 | WO2000020642A1 Prevention of adhesions |
| 04/13/2000 | WO2000020640A1 A novel method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancers |
| 04/13/2000 | WO2000020621A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 04/13/2000 | WO2000020606A1 Method for the production of (poly)peptides by using truncated variants of the sv40 large t antigen with an intact n terminus |
| 04/13/2000 | WO2000020602A2 Delta 6 and delta 12 desaturases and modified fatty acid biosynthesis and products produced therefrom |
| 04/13/2000 | WO2000020598A1 Peptides useful for reducing symptoms of toxic shock syndrome and septic shock |
| 04/13/2000 | WO2000020592A1 Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
| 04/13/2000 | WO2000020590A2 G-protein coupled receptor proteins |
| 04/13/2000 | WO2000020587A2 Cancer associated antigens and uses therefor |
| 04/13/2000 | WO2000020581A1 Mage-a3 peptides presented by hla class ii molecules |
| 04/13/2000 | WO2000020576A2 Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein |
| 04/13/2000 | WO2000020562A1 A novel lymphocyte population expressing intracellular mo2 |
| 04/13/2000 | WO2000020460A1 Methods for producing human tumor antigen specific antibodies |
| 04/13/2000 | WO2000020450A2 Calcium channel alpha-2/delta gene |
| 04/13/2000 | WO2000020448A2 Nlk1 -interacting proteins |
| 04/13/2000 | WO2000020447A2 Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses |
| 04/13/2000 | WO2000020444A1 Novel peptides |
| 04/13/2000 | WO2000020443A1 Novel peptides |
| 04/13/2000 | WO2000020438A1 G protein-coupled receptor resembling the thrombin receptor |
| 04/13/2000 | WO2000020434A1 Cadherin-like asymmetry protein-1, and methods for its use |
| 04/13/2000 | WO2000020043A1 A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers |
| 04/13/2000 | WO2000020041A2 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent |
| 04/13/2000 | WO2000020037A1 A novel component in the hedgehog signalling pathway |
| 04/13/2000 | WO2000020032A1 RECOMBINANT CAT ALLERGEN, Fel dI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY |
| 04/13/2000 | WO2000020031A1 Methods for identification, diagnosis, and treatment of breast cancer |
| 04/13/2000 | WO2000020030A1 Anti-inflammatory alpha2, beta1 integrin-related substances or antibodies |
| 04/13/2000 | WO2000020029A1 Genes differentially expressed in cancer cells to design cancer vaccines |
| 04/13/2000 | WO2000020027A2 Methods for therapeutic vaccination |
| 04/13/2000 | WO2000020020A2 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
| 04/13/2000 | WO2000020011A1 Isolated dna encoding human h3 histamine receptor |
| 04/13/2000 | WO2000019988A1 NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF |
| 04/13/2000 | WO2000003015A3 Human transport protein homologs |
| 04/13/2000 | WO2000000634A3 METHODS OF INHIBITING $i(HELICOBACTER PYLORI) |
| 04/13/2000 | WO2000000608A3 Immune system molecules |
| 04/13/2000 | WO1999064576A3 Human genes differentially expressed in colon cancer |
| 04/13/2000 | WO1999055720A9 Targeted gene delivery to cells by filamentous bacteriophage |
| 04/13/2000 | WO1999050637A3 Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof |
| 04/13/2000 | DE19907094C1 Use of antibodies capable of blocking human thyroid-stimulating hormone receptor to treat hyperthyroidism and endocrine orbitopathy |
| 04/13/2000 | DE19859110A1 Bispezifische und trispezifische Antikörper, die spezifisch mit induzierbaren Oberflächenantigenen als operationelle Zielstrukturen reagieren Bispecific and tri-specific antibodies which specifically react with inducible surface antigens as operational targets |
| 04/13/2000 | DE19852800C1 Production of antibodies to a polypeptide encoded by a known DNA sequence comprises binding of antibodies produced by DNA vaccination to immobilized recombinantly expressed polypeptide |
| 04/13/2000 | CA2354863A1 Prevention of adhesions |
| 04/13/2000 | CA2347120A1 Nlk1 -interacting proteins |
| 04/13/2000 | CA2346496A1 Novel th2-specific molecules and uses thereof |
| 04/13/2000 | CA2346326A1 A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers |
| 04/13/2000 | CA2346217A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 04/13/2000 | CA2346134A1 G protein-coupled receptor resembling the thrombin receptor |
| 04/13/2000 | CA2346068A1 A novel lymphocyte population expressing intracellular mo2 |
| 04/13/2000 | CA2346048A1 Methods for identification, diagnosis, and treatment of breast cancer |
| 04/13/2000 | CA2345881A1 Bone marrow-derived serum proteins |
| 04/13/2000 | CA2345817A1 Novel methods for therapeutic vaccination |
| 04/13/2000 | CA2345440A1 Genes differentially expressed in cancer cells to design cancer vaccines |
| 04/13/2000 | CA2345408A1 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent |
| 04/13/2000 | CA2345377A1 Novel secreted proteins and polynucleotides encoding them |
| 04/13/2000 | CA2345045A1 G-protein coupled receptor proteins |
| 04/13/2000 | CA2345023A1 Peptides useful for reducing symptoms of toxic shock syndrome and septic shock |
| 04/13/2000 | CA2345000A1 A novel method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancers |
| 04/13/2000 | CA2344995A1 Cancer associated antigens and uses therefor |
| 04/13/2000 | CA2344973A1 Oxidoreductase molecules |
| 04/13/2000 | CA2344765A1 Novel peptides |
| 04/13/2000 | CA2344551A1 P-conotoxin peptide |
| 04/13/2000 | CA2344266A1 Cadherin-like asymmetry protein-1, and methods for its use |
| 04/13/2000 | CA2341351A1 Alpha-2/delta gene |
| 04/12/2000 | EP0992584A2 Purified mammalian FLT3 ligands and agonists and antagonists thereof |
| 04/12/2000 | EP0992579A1 Stem cell factor |
| 04/12/2000 | EP0992243A1 Prophylactic/remedial agent |